B.R.A.H.M.S.

B.R.A.H.M.S. is a leading global provider of specialty diagnostic tests and automated immunoassay systems, specializing in the development of innovative biomarkers for critical care and emergency medicine. The company is best known for its gold-standard Procalcitonin (PCT) assay, which is used worldwide to diagnose sepsis and guide antibiotic stewardship. B.R.A.H.M.S. also maintains a strong portfolio in endocrinology, cardiology, and prenatal screening, utilizing its proprietary TRACE (Time-Resolved Amplified Cryptate Emission) technology. Since its acquisition by Thermo Fisher Scientific in 2009, the company has operated as a key component of the Clinical Diagnostics Division. Its products are integrated into major laboratory platforms through extensive licensing agreements with other diagnostic leaders.